SCHEMBL5848314

SCHEMBL5848314

[Li]Cc1ccno1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7045074 0.76
SCHEMBL916741 0.74
SCHEMBL356231 0.74
SCHEMBL5263447 0.74
SCHEMBL1752092 0.74
Hydrochloric Acid SCHEMBL5212534 0.72
SCHEMBL11892701 0.70
SCHEMBL9553682 0.70
SCHEMBL16068283 0.70
SCHEMBL358647 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7022706-B2 Pharmaceutical compositions and methods for use TARGACEPT, INC. (US) 2006-04-04 US disclosed
US-20040152723-A1 Pharmaceutical compositions and methods for use CLARK THOMAS JEFFREY (US) 2004-08-05 US disclosed
WO-2004009599-A1 FIVE-MEMBERED HETEROAROMATIC OLEFINIC AZACYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS INHIBITORS OF NCOTINIC CHOLINERGIC RECEPTORS TARGACEPT, INC. (US) 2004-01-29 WO disclosed
US-6624167-B1 Compounds that are capable of affecting nicotinic cholinergic receptors. A wide variety of conditions and disorders, and particularly conditions and disorders associated with dysfunction of the central and autonomic nervous systems can TARGACEPT, INC. 2003-09-23 US disclosed
US-20020160998-A1 Pharmaceutical compositions and methods for use TARGACEPT, INC. 2002-10-31 US disclosed